:: portfolio news ::
Xanthus
Xanthus Gets SPA Clearance For Trials In Secondary AML >>
US Genomics:
U.S. Genomics Recognized for Outstanding Entrepreneurship by the National Science Foundation (NSF)
>>
Xanthus
Xanthus' Symadex Can Reverse Disease in Preclinical MS Animal >>
US Genomics:
Growing pains at U.S. Genomics >>
Stargus
C-COR announces agreement on
terms to purchase Stargus >>
Bus-Tech
The importance of being flexible:
Bus-Tech adapts >>
MEMSIC
Leaders from fourteen companies
named New England Entrepreneur
of the Year Award >>
About Us
|
Portfolio
|
Team
|
Contact Us
© 2004 Still River Funds. All Rights Reserved.